Breaking News, Collaborations & Alliances

J&J Expands Manufacturing Capabilities for its COVID-19 Vaccine Candidate

Inks deal with CDMO Emergent BioSolutions as part of its investment

By: Contract Pharma

Contract Pharma Staff

The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) and Emergent BioSolutions have formed a collaboration to support the manufacturing of J&J’s lead investigational COVID-19 vaccine candidate. This is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of J&J’s COVID-19 vaccine candidate, and further the company’s goal to supply more than one billion doses of the vaccine globally.   “We have set a hig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters